Partnering with Distruptive Pharma

Partnership model

Disruptive Pharma operates a flexible partnering model built around the Formulite® technology platform, enabling collaboration through both licensing and development projects, depending on partner objectives and development stage.

We collaborate across early formulation feasibility to late-stage optimization and lifecycle management, supporting the development of improved oral medicines that deliver clinical, commercial and patient value.

  • Partnering and Development Agreements – formulation and product development projects for external partners, ranging from early feasibility assessments to advanced formulation development, product optimization, scale-up and support for lifecycle management programs.

  • Platform Commercialization – strategic collaborations with CDMOs and other industrial partners to enable broader industrial use of Formulite®.

Partnering and Development Agreements

Disruptive Pharma collaborates with external partners on formulation- and product development projects where Formulite® is applied to address key challenges in oral drug development. These tailored B2B projects range from early feasibility assessments to advanced formulation development and scale-up, integrated into the partner’s existing development and lifecycle management programs.

Typical formulation challenges addressed include:

  • Improving bioavailability for poorly soluble or dissolution-limited compounds
  • Enabling high drug loading and flexible dosing
  • Simplifying formulation design and manufacturing
  • Reducing polymer burden and solvent-intensive processing

Projects are structured with clear technical scope, timelines, and decision points, enabling efficient evaluation of Formulite and informed development decisions.

Partner with us

Platform Commercialization

Disruptive Pharma collaborates with contract development and manufacturing organizations (CDMOs), and other industrial partners to enable broader industrial use of Formulite® establish capacity for scale-up and commercial manufacturing, and create the conditions for future licensing and partnership opportunities.

Partner with us

Intellectual property framework

Disruptive Pharma holds exclusive worldwide rights to manufacture and use the Formulite technology in pharmaceutical applications. The intellectual property portfolio includes granted and pending patents covering drug loading and formulation principles involving mesoporous magnesium carbonate (MMC).

In addition, reformulated drug products can be protected through formulation-specific patents, supporting the use of Formulite® in lifecycle management and product differentiation strategies.

Formulite® is made available to development partners across two use cases:

  • Formulation of drugs in development, including novel chemical entities (NCE)
  • Reformulation of established active pharmaceutical ingredients (API)

In both cases, Disruptive Pharma works closely with partners to define appropriate IP strategies and maximize the value of the underlying innovation, enabling the translation of formulation advances into novel, protectable, and commercially viable oral drug products.

Lifecycle management

For many drugs side effects may limit the usage despite a highly efficacious mechanism of action, often driven by low bioavailability and consequently high API dosing. Formulite is ideally suited to address the root cause of the side effects and improve patient tolerability of these drugs. With an established regulatory pathway and exclusivity protection through a formulation patent, Formulite® is ideally suited as a lifecycle management initiative. Formulite®  offers an attractive combination of excellent amorphous API stability, improved bioavailability, scalable manufacturing and stronger patent protection for the product.

Formulite® is expected to be regulated as an excipient, with reformulated products following applicable regulatory guidelines.